The job cuts and consolidation efforts are expected to save the debt-ridden drugmaker $3 billion in annual costs, after an upfront charge of $700 million in severance expenses and facility closures.
Its U.S. consolidation efforts will include closing sites in Cambridge, Mass., Washington, D.C., Horsham, Pa., and New York City. In addition, some other sites may be sold to competitors, according to the report.
The company has yet to decide the location of its consolidated U.S. site.
The announcement comes after Teva lost a lawsuit Monday that attempted to block Mylan’s generic multiple sclerosis drug from entering the U.S. market.
More articles on supply chain:
10 recent pharma layoffs
Sanofi urges Philippine government to lift suspension of its dengue vaccine
Medline to relocate supply distribution center in Maryland, triple its workforce
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
